IGF-1 DES: Dosage, Protocol, and Research Guide
Truncated IGF-1 variant with enhanced potency
Mechanism
More potent than IGF-1 due to reduced binding protein affinity, directly stimulates muscle growth and repair
Protocol at a glance
| Starting dose | 20mcg |
|---|---|
| Maintenance dose | 40mcg |
| Maximum dose | 50mcg |
| Frequency | Post-workout |
| Typical duration | 4-6 weeks |
| Route | Intramuscular |
| Injection site | Target muscle |
| Timing | Immediately post-workout |
Side effects
- Hypoglycemia
- Localized muscle growth
Contraindications
- Active cancer
- Diabetic retinopathy
Protocol notes
- Site-specific growth
- Very short half-life
- Monitor blood glucose
- Bilateral injections recommended
- Limited systemic effects
Frequently asked questions
Is IGF-1 DES legal?
IGF-1 DES is classified as a research peptide and is not FDA-approved for human use. In most jurisdictions, it is available for research purposes only and not approved as a pharmaceutical for medical treatment. Always verify your local regulations before obtaining or using any research compounds, and consult with a licensed physician regarding legality and appropriate medical supervision in your area.
How does IGF-1 DES differ from regular IGF-1?
IGF-1 DES is a truncated variant with significantly enhanced potency compared to standard IGF-1. The key difference lies in its reduced binding protein affinity, which allows IGF-1 DES to bypass traditional regulatory mechanisms and achieve more direct tissue engagement. This structural modification results in more efficient muscle stimulation and repair signaling, along with predominantly localized effects rather than systemic distribution. The very short half-life further contributes to its site-specific action.
What are the typical dosing protocols for IGF-1 DES?
Standard protocols begin with 20 micrograms, advance to a maintenance dose of 40 micrograms, and may reach a maximum of 50 micrograms. Administration occurs immediately post-workout via intramuscular injection directly into the target muscle. Research protocols typically run for 4-6 week cycles. Bilateral injections are recommended to prevent localized asymmetrical growth. All dosing should occur under medical supervision.
When should I inject and where?
IGF-1 DES should be injected immediately post-workout, capturing the muscle during its most anabolic state following training-induced damage. Administration is via intramuscular injection directly into the target muscle group you wish to develop. Injecting into specific muscle belly allows concentrated growth at that location. Bilateral injections into complementary muscle groups are recommended to maintain symmetrical development.
What are the main side effects of IGF-1 DES?
The primary side effects include hypoglycemia and localized muscle growth at injection sites. Blood glucose monitoring is essential, as hypoglycemic episodes require immediate management. While localized muscle growth is often desired, asymmetries develop if injections are not distributed bilaterally. Individuals with active cancer or diabetic retinopathy must not use IGF-1 DES. Any adverse effects warrant immediate medical attention.
How long should I cycle IGF-1 DES?
Typical research protocols extend across 4-6 week cycles, balancing the peptide's efficacy with safety considerations and recovery windows. This duration allows sufficient time for localized muscle growth and adaptation while minimizing prolonged exposure to potential side effects. Post-cycle monitoring of blood glucose and physical recovery is important before considering subsequent cycles. Medical oversight throughout the entire cycle remains essential.
What lab markers should I monitor?
Blood glucose monitoring is the primary lab marker requiring attention during any protocol. Regular glucose testing helps identify hypoglycemic episodes before they become symptomatic. Depending on individual health status and medical supervision, your physician may recommend additional monitoring of metabolic parameters and insulin sensitivity. Baseline testing before beginning and follow-up testing throughout remain essential.
Are there contraindications to using IGF-1 DES?
Yes. IGF-1 DES is absolutely contraindicated in individuals with active cancer or diabetic retinopathy. These conditions represent situations where growth-stimulating effects could cause serious harm. Additionally, anyone with significant metabolic disorders, uncontrolled diabetes, or other serious medical conditions must consult a licensed physician. A comprehensive medical evaluation is essential before starting any research protocol.
More Athletic Performance peptides · All peptide guides · Free dose calculator
Educational reference only — not medical advice. Work with a qualified clinician.